Compare Entegris Inc (ENTG) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Nuvalent Inc — how do they compare? Entegris Inc trades at $133.62 (market cap $21.12B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Entegris Inc is far larger — about 2.2× Nuvalent Inc's market cap, and Entegris Inc pays a 0.29% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| ENTG | NUVL | |
|---|---|---|
Market Cap | $21.12B | $9.81B |
Sector | Technology | Technology |
52-Week High | $184.00 | $123.96 |
52-Week Low | $68.80 | $72.16 |
Enterprise Value | $24.44B | $8.52B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $140.63, up 3.2% on the day, with a bearish technical signal and premium valuation metrics. The company reported strong Q1 2026 earnings, beating estimates, and maintains a solid cash flow position. Recent news highlights a quarterly dividend declaration and a non-exclusive cross-licensing agreement for EUV lithography technology.
The outlook is mixed: Wall Street analysts maintain a bullish consensus with a $178.40 price target (26.9% upside), citing AI-driven semiconductor demand as a catalyst. However, risks include elevated valuation multiples, competitive pressures in the semiconductor materials sector, and execution challenges in maintaining recent earnings momentum.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
